Lior Carmon

Title: Lior Carmon: Innovator in Anti-Tumor Vaccines

Introduction

Lior Carmon is a prominent inventor based in Tel Aviv, Israel. He has made significant contributions to the field of cancer research, particularly in the development of anti-tumor vaccines. With a total of 3 patents to his name, Carmon is recognized for his innovative approaches to combating cancer.

Latest Patents

Carmon's latest patents focus on tumor-associated antigens and their use in anti-tumor vaccines. One of his inventions relates to colon and prostate tumor-associated antigen peptides derived from prostate-specific G protein-coupled receptor (PSGR) and six-transmembrane epithelial antigen of prostate (STEAP). This invention also includes polynucleotides encoding these peptides and pharmaceutical compositions designed to treat or inhibit the development of colon or prostate cancer. Another patent emphasizes tumor-associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate-specific antigen (PSA), and Prostate acid phosphatase (PAP), among others. These peptides are intended for use as anti-tumor vaccines to prevent or cure various cancers, particularly bladder, prostate, and breast cancers.

Career Highlights

Lior Carmon is associated with Yeda Research and Development Co. Ltd., where he continues to advance his research in cancer immunotherapy. His work has garnered attention for its potential to improve treatment outcomes for patients suffering from various forms of cancer.

Collaborations

Carmon collaborates with notable colleagues, including Lea Eisenbach and Boaz Tirosh, who contribute to his research endeavors. Their combined expertise enhances the development of innovative solutions in the fight against cancer.

Conclusion

Lior Carmon stands out as a key figure in the field of cancer research, with his patents paving the way for new anti-tumor vaccines. His dedication to innovation and collaboration continues to inspire advancements in medical science.